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Abstract Gastric cancer is the fourth cause of death by
cancer in Spain and a significant medical problem.
Molecular biology results evidence that gastroesophageal
junction tumors and gastric cancer should be considered as
two independent entities with a different prognosis and
treatment approach. Endoscopic resection in very early
tumors is feasible. Neoadjuvant and adjuvant therapy in
locally advanced resectable tumor increase overall survival
and should be considered standard treatments. In stage IV
tumors, platinum–fluoropyrimidine-based schedule, with
trastuzumab in HER2-overexpressed tumors, is the first-
line treatment. Different therapies in second line have
demonstrated in randomized studies their clear benefit in
survival improvement.
Keywords Gastric adenocarcinoma  Cardia  Diagnosis 
Treatment  Clinical guidelines
Introduction
Gastric cancer (GC) is a major contributor to the global
cancer burden. In 2012, there were an estimated 951,000
new cases worldwide, 6.8 % of the total, making GC the
fifth most common malignancy [1]. GC is the third leading
cause of cancer death in both sexes worldwide with
723,000 deaths, 8.8 % of the total. In Spain, GC was the
sixth most common malignancy, with 7810 new cases and
5389 deaths [2]. Geographically, almost two-thirds occur in
Asia, with 43 % of total global cases in China. Incidence
rates are low in developed regions such as North America
and Western Europe. GC is more frequent among males
than in females (11.0 versus 5.1 per 100,000) and its
incidence increases with age (peak presentation is between
65- and 74-year old). Mortality age-standardized rate is 9.7
in men and 4.6 in women [3]. The most important familial
cancer syndrome is hereditary diffuse gastric cancer syn-
drome [mutations in the germline E-cadherin mutations
(CDH1) gene] [1].
Although often reported as a single entity, GC can
generally be classified [4] into two topographical cate-
gories: (1) cardia gastric cancer (CGC) arising in the area
of the stomach adjoining the esophageal–gastric junction
[5], and (2) non-CGC (NCGC) arising from more distal
regions of the stomach. Risk factors for CGC include
obesity, gastro-esophagus reflux disease (GORD) and
Barrett’s esophagus. NCGC, however, is strongly
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associated with Helicobacter pylori infection, socioeco-
nomic status (SES), excess nitrates, and atrophic gastritis.
Both types are influenced by cigarette smoking and by low
intake of fruits and vegetables. Given these differences,
there is increasing interest in describing the worldwide
burden of CGC and NCGC subsites separately [6]. CGC:
there were 260,000 new cases, comprising 27 % of total
gastric cancer worldwide (30 % in men and 21 % in
women). Age-standardized rate was 3.3 per 100,000 (5.3
versus 1.6 in men and women, respectively). NCGC: there
were 691,000 new cases, 70 % in men and 79 % in women.
Age-standardized rate was 8.8 per 100,000 (12.1 versus 5.9
in men and women, respectively). In most countries, CGC
incidence rates are lower than NCGC rates (91 % of 184
GLOBOCAN countries).
These clinical guidelines aim to offer succinct, practical
recommendations for diagnosis, treatment, and follow-up
of GC.
Molecular classification of gastric cancer
Gastric cancer is known as a heterogeneous disease, which
may be divided into subgroups based on histological,
anatomical, epidemiological, and also molecular classifi-
cations [7–12].
Despite such incredible advance in our knowledge of
gastric cancer genomics, there is little overlap between the
published classifications, and the reproducibility of the
different studies is very poor [13]. Therefore, it is difficult
to compare expression data from different studies and such
inconsistency limits our ability to develop robust and
reliable molecular models.
Molecular prognosis of gastric cancer
There is no one single molecular alteration that has been
universally accepted as independent prognostic factor in
gastric cancer. Many gene expression signatures have been
able to classify tumors into intrinsic subtypes and predict
the survival of GC patients. Some studies have showed that
gene expression profiling can predict patients with a high
risk for recurrence after curative surgery [14–16]. Other
studies using gene expression data with proper clinical
information have developed predictive models that could
identify long survivors, either by identifying specific gene
signatures that correlated with the overall survival [17–19]
or by identification of Genomic signatures that could suc-
cessfully predict the relapse of GC, specially in form of
peritoneal relapse [20].
Despite all these profits in the development of prog-
nostic and predictive molecular models for GC, they are at
an early stage and in need of substantial improvement to be
ready for its clinical implementation.
Diagnosis and staging
Diagnosis
Gastroscopy and biopsy of suspicious lesions are the basis
for definitive diagnosis. Histology is reported according to
World Health Organization criteria [21] and Lauren clas-
sification (intestinal and diffuse). Immunohistochemistry
(IHC) determines HER2 overexpression in advanced dis-
ease, according to GC-specific criteria [22], to decide
trastuzumab treatment.
Staging
WHO performance status (PS), nutritional status, and
comprehensive geriatric assessment in the elderly, as
well as physical exam, liver, renal and blood tests, and
tumor stage should be considered before choosing
treatment;
Locoregional disease:
• Endoscopic ultrasound (EUS) and ultrasound-guided
fine-needle aspiration of suspicious lymph nodes
inform about locoregional disease spread and are
optimal to distinguish T2–4 staging [IIA] [23] or
• Esophagus-gastro-duodenal transit, when endoscopy
cannot be performed.
Distant disease:
• Computed tomography (CT) is standard to confirm
metastases (IA).
• Laparoscopy, peritoneal washings, and cytology is
mandatory in locally advanced gastric (T3–4 and/or
node-positive disease) and esophagogastric junction
cancer [IIA] [24]
• The value of integrated PET/CT in patients who are
offered curative surgery is a subject to debate, although
it may be convenient in large tumor size, non-signet
ring cell, non-mucinous, non-diffuse carcinoma type,
and glucose transporter 1-positive expression on
immunohistochemistry [25].
• Combinations of CEA, CA19-9, and CA72-4 are the
most effective serum tumor markers for staging,
detection of recurrence, or evaluation of the response
[26].
• Staging is performed according to the 2010 AJCC TNM
classification, 7th edition (Table 1) [4]. Four major
groups are considered for clinical management pur-
poses (Table 2).
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Table 1 Tumor stage of gastric cancer according to AJCC 2010
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria
T1 Tumor invades lamina propria, muscularis mucosae, or submucosa
T1a Tumor invades lamina propria or muscularis mucosae
T1b Tumor invades submucosa
T2 Tumor invades muscularis propriaa
T3 Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structuresb
T4 Tumor invades serosa (visceral peritoneum) or adjacent structuresb
T4a Tumor invades serosa (visceral peritoneum)
T4b Tumor invades adjacent structures
Nx Regional lymph node(s) cannot be assessed
N0 No regional lymph node metastasisc
N1 Metastasis in 1–2 regional lymph nodes
N2 Metastasis in 3–6 regional lymph nodes
N3 Metastasis in seven or more regional lymph nodes
N3a Metastasis in 7–15 regional lymph nodes
N3b Metastasis in 16 or more regional lymph nodes
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Stage T N M
Anatomic stage/prognostic groups
0 Tis N0 M0
IA T1 N0 M0
IB T2 N0 M0
T1 N1 M0
IIA T3 N0 M0
T2 N1 M0
T1 N2 M0
IIB T4a N0 M0
T3 N1 M0
T2 N2 M0
T1 N3 M0
IIIA T4a N1 M0
T3 N2 M0
T2 N3 M0
IIIB T4b N0 M0
T4b N1 M0
T4a N2 M0
T3 N3 M0
IIIC T4b N2 M0
T4b N3 M0
T4a N3 M0
IV Any T Any N M1
cTNM is the clinical classification, pTNM is the pathologic classification
Primary tumor (T), Regional lymph nodes (N)
a A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser
omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified T3. If there is perforation
of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified T4
b The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney,
small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any
of these sites, including the stomach
c A designation of pN0 should be used if all examined lymph nodes are negative, regardless of the total number removed and examined
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Treatment
Early gastric cancer
Endoscopic resection
Early GC (T1a) may be amenable to endoscopic resection
if it is well differentiated,\2 cm, confined to the mucosa,
and non-ulcerated. Intestinal Lauren histology and no
evidence of lympho-vascular invasion also indicate
mucosectomy in: intramucosal cancers without ulceration,
regardless of tumor size; ulcerated intramucosal cancers
\3 cm, or cancers with early invasion into the submucosa
measuring\3 cm, endoscopic submucosal dissection has
proven more effective than endoscopic mucosal resection,
but requires greater skills and instrumentation and entails
significant risk of complications, including perforation
[27]. The risk of lymph node metastases following endo-
scopic resection by experts remains low in these tumors
[28]. In less experienced centers, limited surgery is an
alternative. T1A GC not meeting criteria for endoscopic
treatment will require less extensive surgery than IB-III
tumors and lymph node dissection can be limited to peri-
gastric and local nodes (Table 3).
Locally advanced disease
Surgery
Complete resection with adequate margins remains the
cornerstone of curative treatment. The type of resection in
GC, subtotal versus total gastrectomy, depends on the
anatomic location of primary tumor. For esophagogastric
junction (EGJ) cancers, a total esophagectomy with a
partial gastrectomy or an extended gastrectomy is generally
performed.
Extent of lymph node dissection remains a subject of
controversy. In eastern Asia, gastrectomy with D2 lymph
node dissection is the standard treatment for curable GC. In
Western countries, two large randomized trials failed to
demonstrate a significant survival benefit for D2 over D1
lymph node dissection. However, mature 15-year follow-
up data from the Dutch trial showed a lower locoregional
recurrence rate and fewer GC-related death with D2 lym-
phadenectomy [29]. A recent meta-analysis of 12 ran-
domized clinical trials confirmed no OS benefit for D2
lymphadenectomy, although a benefit was seen among
patients who had resection without splenectomy and/or
pancreatectomy [30]. There is uniform consensus that
lymphadenectomy must include at least 15 lymph nodes.
Gastrectomy with D2 lymph node dissection is a recom-
mended procedure (2B), but should be performed by
experienced surgeons in high-volume centers. Routine
pancreatectomy and splenectomy are no longer recom-
mended with D2 lymph node dissection.
Neoadjuvant treatment
Chemotherapy (CT) A study by the EORTC (40954) in
patients with locally advanced cancer of the stomach or
EGJ found a significantly higher rate of R0 resection
among patients receiving neoadjuvant CT; however, no
statistically significant difference in survival was reached
[31]. Some meta-analysis in GC has been conduced with
conflicting results. A meta-analysis in EG cancers, where
several EGJ were included [32], showed a survival benefit
for neoadjuvant CT. Currently, we should consider
neoadjuvant chemotherapy in gastroesophageal cancer
(IB).
Chemoradiotherapy (CRT) The phase III study POET
compared preoperative CT with preoperative CRT in
patients with locally advanced adenocarcinoma of the EGJ.
Patients in the CRT group had a significant higher patho-
logic complete response, but statistical significance was not
achieved for overall survival (OS) [33]. The phase III
CROSS trial compared neoadjuvant CRT versus surgery
alone in patients with squamous cell carcinoma and ade-
nocarcinoma of the esophagus or EGJ, with a significant
increase of OS in the neoadjuvant group [34]. The meta-
analysis published by Sjoquist et al. [32] supports a sur-
vival benefit for neoadjuvant CRT compared to surgery
Table 2 Prognosis and treatment options
Groups Early resectable disease
(10 %)
Locally advanced
resectable disease
Locally advanced
unresectable disease (20 %)
Metastatic disease
(30 %)
Stages Stages 0–I; II–IIIC Some IIIB–IIIC IV
5-year/median
OS
70 % 30–40 % 12–14 months 9–11 m with CT
4 m without CT
Treatment Surgery or Endoscopic
resection
Perioperative, Neoadjuvant o
Adjuvant ttm.
CT CT
CT chemotherapy, ttm treatment
Clin Transl Oncol (2015) 17:996–1004 999
123
alone for esophageal and EGJ cancer. Preoperative com-
bined CRT is now the preferred approach for localized EGJ
and gastric cardia cancers (IB). However, it is still an
experimental procedure in potentially resectable non-cardia
gastric adenocarcinomas (2B).
Perioperative treatment
The theoretical advantages of perioperative treatment are
the potential increase of the complete resection (R0) rate, a
better tolerability profile and increased probability of
treatment compliance, early systemic treatment of micro-
metastatic disease, and an ideal scenario to assess the
efficacy of scheduled treatment, as well as new agents.
Two phase III, adequately powered trials in Western
countries, the MAGIC [35] and the FNLCC/FFCD 9703
[36], and some recent meta-analysis [37] have shown that
perioperative chemotherapy (CT) significantly increases
R0 rates, disease-free survival (DFS), and OS, and does not
significantly increase perioperative complications or mor-
tality with tolerable grade 3–4 toxicity rates (Table 1).
These results have led to the adoption of perioperative CT
as a standard approach for medically fit patients with
resectable locally advanced (cT2 or higher, any N) distal
esophageal, esophagogastric junction, or gastric tumors
[IA] throughout most of European countries and other parts
of the world.
Regarding the role of targeted agents in the periopera-
tive setting, two phase II trials have tested the combination
of trastuzumab and CT in HER-2-positive patients showing
promising R0 rates and pathologic complete responses
(pCR). However, the addition of bevacizumab to a peri-
operative regimen of epirubicin, cisplatin, and capecitabine
(ECX) did not improve survival [38].
The potential benefit of adding postoperative or preop-
erative CRT to standard perioperative CT is being evalu-
ated in two trials.
Adjuvant treatment
Chemoradiation In patients with resected gastric or GEJ
adenocarcinoma stages IB–IV (M0), the INT-0116 trial
reported better OS (HR 1.35; p = 0.005) and DFS (HR
1.52; p\ 0.001) with the MacDonald regimen (5FU/LV
Table 3 Treatment recommendations
Stage Details Treatment
Early stage: Tis
T1a
T1a
T1b
T1b
Well dif./\2 cm/non-ulcerated/intestinal
Others non-ulcerated
\3 cm
Others
Endoscopic resection
Endosc. resect mucosectomy/surgery
Submucos. resect/surgery
Surgery
Stage I Surgery
Locally Advanced (Stage II–III) Cardias GC Neoadjuvant CT (IB)
Or CRT (IA)
Or Perioperative CT (IB)
Or Adjuvant CT (IA)
Or Adjuvant CRT (IB)
Non-cardias GC Perioperative CT (IB)
Or Adjuvant CT (IA)
Or Adjuvant CRT (IB)
Advanced disease (Stage IV) First-line CT
HER2? Cisplatin–Fluorop (IB)
HER2 negative PFluorop or EPFluorop (IA)
Or TCF (IB)
Or FOLFIRI or IF (IB)
Second-line CT Irinotecan (IA)
Or Docetaxel (IA)
Or Paclitaxel (IB)
Or Ramucirumab (IB)
Or Paclitaxel–Rramucirum (IB)
Fluorop. 5Fu or Capecitabine, P cisplatin or oxaliplatin, TCF taxotere ? cisplatin ? 5FU
1000 Clin Transl Oncol (2015) 17:996–1004
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plus radiotherapy) versus surgery alone [39] (IB). In the
13-year follow-up, the benefit of adjuvant CRT was
maintained and not substantial long-term toxicities were
reported [40]. The CALGB 80101 compared the INT-0116
regimen with ECF (epirubicin, cisplatin, 5FU before and
after 5FU/RT) in resected GEJ or gastric cancer without
observing differences in 3-year OS (52 and 50 % for ECF
and 5FU/LV, respectively). In HER2-positive tumors, the
phase II TOXAG trial will analyze the safety of adjuvant
oxaliplatin, capecitabine’, and trastuzumab with
radiotherapy.
Chemotherapy The benefit of adjuvant CT has also been
reported. An absolute increment of 6 % in OS (HR 0.82;
p\ 0.001) and a better DFS (HR 0.82; p\ 0.001) were
published in a large, individual patient-level meta-analysis
of adjuvant 5FU-based chemotherapy versus surgery alone
in resected GC [41] [I,A]. However, the preferred combi-
nation chemotherapy could not be determined.
In addition, the ACTS-GC randomized phase III trial
showed a significantly better 3-year OS with S-1 for 1 year
than with observation in D2-resection stage II or III GC
patients [42] [IB]. In the update after 5 years of follow-up,
the benefit was maintained in the S-1 group [43]. In the
same type of patients, the XELOX regimen was superior to
surgery alone in the CLASSIC phase III trial. With a
median 5-year follow-up, the estimated 5-year DFS was 68
versus 53 % and the estimated 5-year OS was 78 versus
69 % in the XELOX and the surgery-only groups,
respectively [44].
Adjuvant chemoradiotherapy vs chemotherapy The
ARTIST trial compared CRT [cisplatin and capecitabine
(XP), with capecitabine and radiation concurrently] versus
chemotherapy alone (XP 9 6 cycles) in patients with at
least D2 lymphadenectomy and R0 resection [45]. With a
7-year follow-up, the DFS (HR 0.74; p = 0.092) and the
OS (HR 1.13; p = 0.527) were similar between the groups.
Subgroup analyses showed that CRT significantly
improved DFS in node-positive disease and with intestinal-
type GC [46]. Finally, the Korean ARTIST II randomized
phase III trial is currently comparing adjuvant S-1 versus
S-1 plus oxaliplatin (SOX), with or without radiotherapy.
Advanced disease
First-line treatment
Several randomized studies and a meta-analysis [47],
comparing palliative CT with the best supportive care
(BSC), have demonstrated that CT increases median
overall survival and improves the quality of life of patients
with advanced gastric cancer [I,A].
Cisplatin-based chemotherapy In the late nineties, it was
proven that regimes based on cisplatin were superior to
other older regimes without cisplatin. Both CF (cisplatin–
5FU) and ECF (epirubicin–cisplatin–5FU) can be consid-
ered standard combinations (IA). Although a meta-analysis
suggests better OS with ECF, there are no randomized
head-to-head comparison studies
Chemotherapy with docetaxel In the Phase III study
V-325 [48], docetaxel, cisplatin, and 5FU (DCF) was
compared with CF. DCF was superior in TTP, OS, and
response rate but was also more toxic. Triplets with Doc-
etaxel can be considered in selected patients (IB).
Oxaliplatin-based chemotherapy Two phase III studies
[49, 50] have suggested that oxaliplatin has similar efficacy
and less toxicity than cisplatin and can replace it in this
setting (IA).
Oral fluoropyrimidines Two phase III studies [49, 51]
have observed no inferiority in efficacy and a more
favorable toxic profile, when replacing 5FU with capeci-
tabine. Another phase III study observed non-inferiority in
efficacy and better convenience and toxicity with cisplatin-
S1 versus CF [52]. Based on these data, oral fluoropyrim-
idines (capecitabine or S-1) can replace 5FU in this setting
[I,A].
Irinotecan combinations Irinotecan/5FU/LV combina-
tions (FOLFIRI, IF) have been compared with CF in two
randomized trials [53, 54] showing similar efficacy and
better tolerance and can be considered adequate options for
these patients (I,B).
Trastuzumab The phase III TOGA [55] analyzed HER-2
status in 3807 patients. Twenty-two per cent were HER-2?
(594) and were randomized to receive chemotherapy alone
(CX or CF) or chemo plus trastuzumab. In the trastuzumab
arm, it was shown a statistically significant increase in the
primary endpoint, which was OS as well as in PFS. A
preplanned analysis of OS in the subgroup of patients with
IHC 3? or IHC 2? with FISH? showed an increase of
5 months OS in the trastuzumab arm (16.8 versus
11.8 months, HR 0.65). According to these results, we can
consider that trastuzumab added to cisplatin ? fluoropy-
rimidines can be considered the standard treatment in
patients with gastric or EGJ advanced HER-2? adenocar-
cinoma [IB].
Second-line chemotherapy
Less than 60 % of patients receive second- or third-line
therapy for gastric cancer in clinical practice [55]. There is
Clin Transl Oncol (2015) 17:996–1004 1001
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evidence that second-line chemotherapy achieves
improvement in quality of life (QOL) and provides a
median overall survival (OS) of 4–6 months [I,A]. Doc-
etaxel, paclitaxel, irinotecan, and a targeted therapy against
vascular endothelial grow factor receptor 2 (VEGFR2) with
ramucirumab have demonstrated a significant benefit in OS
in phase III trials [I,B]. Two recent meta-analysis have
shown a significant reduction in the risk of death [56, 57]
[I,A]. The reduction was HR = 0.55 for irinotecan, and
HR = 0.71 for docetaxel [57].
Irinotecan The first study randomized 40 patients
between irinotecan and best supportive care (BSC).
Irinotecan showed a statistically significant survival benefit
over BSC (median OS 4 versus 2.4 months, respectively)
[I,B] [58].
A Korean trial randomized patients to BSC, to 3-weekly
docetaxel or 2-weekly irinotecan. Chemotherapy showed a
significant survival benefit (median OS 5.3 versus
3.8 months, HR = 0.65) over BSC alone [I,B] [59].
Docetaxel The UK COUGAR-02 trial randomized 168
patients to 3-weekly docetaxel versus BSC. Docetaxel
improved median overall survival over BSC (5.2 months
versus 3.6 months, respectively, HR = 0.67) [I,B]. Global
quality of life (QOL) scores were similar between the two
arms [60].
Paclitaxel A phase III trial with 219 Asian patients did
not show a superiority of irinotecan against paclitaxel [I,B]
(median OS 8.4 versus 9.5 months, respectively,
HR = 1.14) [61].
Ramucirumab has shown a statistically significant effi-
cacy as monotherapy (REGARD) or in combination with
paclitaxel (RAINBOW). REGARD randomized 445
patients to ramucirumab versus placebo. Ramucirumab
showed a significant OS benefit (5.2 months versus
3.8 months, HR = 0.77) over placebo [I,B] [62].
RAINBOW randomized 665 patients to ramucirumab
plus paclitaxel or to paclitaxel plus placebo. Ramucirumab
plus paclitaxel arm showed a significantly superior OS
(9.6 months versus 7.3 months, HR = 0.80) over pacli-
taxel monotherapy [I,B] [63].
Future lines and targeted drugs
Since the approval of Trastuzumab in advanced HER2
positive gastric cancer, in 2010, there have been an
increasing number of molecules and targets entering the
preclinical and clinical research programs in GC.
New strategies underway to improve the results of
trastuzumab in HER2-positive GC include the use of
antibody–drug conjugates to deliver cytotoxic agents such
trastuzumab emtansine (T-DM1) [64] or its combination
with new monoclonal antibodies (MoAbs) that targets a
different extracellular dimerization domain (Pertuzumab)
[65]. Antiangiogenic therapy with Ramucirumab, a fully
human immunoglobulin (Ig) G1 monoclonal antibody tar-
geting VEGFR-2, has demonstrated improved survival
both as monotherapy and in combination with paclitaxel
[62, 63] in the second-line setting. By the contrary, 2
MoAbs targeting MET were unsuccessfully tested in this
disease [66, 67].
Two recently communicated clinical trials have
demonstrated some early signs of activity of both antiPD-1
and antiPD-L1 antibody immune checkpoint inhibitors in
upper GI malignancies [68, 69].
Follow-up In the setting of operable gastric cancer, a
regular follow-up may allow treatment of symptoms and
early detection of recurrence, though there is no evidence
that it improves survival outcomes [III, B]. If relapse/dis-
ease progression is suspected, then physical examination,
blood tests, and radiological investigations or endoscopy
should be carried out. We recommend anamnesis and
physical examination every 3–6 months in the first 3 years
following surgical intervention and then every 6–12 months
during years 4 and 5 [V]. The benefit of following up the
patients beyond year 5 is controversial [70].
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